Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 9,154 matching trials from the live ClinicalTrials.gov search.

Filters: Rochester, Minnesota Clear all

Conditions: Achalasia
Interventions: POPE; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Acute Liver Failure
Interventions: N-acetylcysteine (NAC), Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more

Conditions: Neoplasms
Interventions: Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, Capecitabine, Bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 63
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 38 more

Conditions: Eye Cancer, Primary Cancer
Interventions: AU-011, SCS Microinjector, Laser; Drug · Device
Lead sponsor: Aura Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Palo Alto, California • Miami, Florida • Boston, Massachusetts + 10 more

Conditions: Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Interventions: Zanzalintinib, Everolimus; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Hepatocellular Carcinoma
Interventions: Cabozantinib tablets, Placebo tablets; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 22
States / cities: Corona, California • Los Angeles, California • San Diego, California + 17 more

Conditions: Interstitial Lung Disease
Interventions: ILD, Healthy, Pneumonia; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 635 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hepatitis C
Interventions: telaprevir, ribavirin, peginterferon alfa-2a; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 57 more

Conditions: Epilepsy, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Biomarkers
Interventions: Not listed
Lead sponsor: Epilepsy Foundation of America; Other
Eligibility: 16 Years to 65 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 10
States / cities: San Francisco, California • New Haven, Connecticut • Miami, Florida + 6 more

Conditions: Identify Characteristics of Colonoscopists During Endoscopy
Interventions: Not listed
Lead sponsor: Artann Laboratories; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 3
States / cities: Santa Barbara, California • Chevy Chase, Maryland • Rochester, Minnesota

Conditions: Sleep Apnea, Obstructive
Interventions: Coblation (radiofrequency-based device); Device
Lead sponsor: ArthroCare Corporation; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and atorvastatin, Atorvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 78
States / cities: Birmingham, Alabama • Northport, Alabama • Sierra Vista, Arizona + 75 more

Conditions: Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, amifostine trihydrate, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 16
States / cities: Scottsdale, Arizona • Indianapolis, Indiana • Burnsville, Minnesota + 12 more

Conditions: Primary Sclerosing Cholangitis, Compensated Cirrhosis
Interventions: Cilofexor; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 16
States / cities: Chandler, Arizona • Pasadena, California • San Francisco, California + 11 more

Conditions: Healthy
Interventions: 5-13C-Glutamine, Bone marrow aspiration; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Arteriovenous Fistula
Interventions: LUTONIX 035 Drug Coated Balloon PTA Catheter; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 22
States / cities: Birmingham, Alabama • Dothan, Alabama • Orange, California + 17 more

Conditions: Breast Cancer
Interventions: Single nucleotide polymorphism (SNP), high performance liquid chromatography, measurements by DXA, questionnaire administration; Genetic · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 4
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more

Conditions: Cancer
Interventions: capecitabine, radiation therapy; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 17
States / cities: Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more

Conditions: Prostate Tumors
Interventions: MR-Guided Laser Ablation; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 95 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alcohol Associated Hepatitis
Interventions: INT-787, Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Fresno, California • Palo Alto, California • Sacramento, California + 17 more

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Tesevatinib; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 62 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 11
States / cities: Los Angeles, California • Denver, Colorado • Kansas City, Kansas + 8 more

Conditions: Lung Cancer, Lung Metastases
Interventions: VGT-309; Drug
Lead sponsor: Vergent Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Duarte, California • Orlando, Florida • Rochester, Minnesota + 2 more

Conditions: Type 1 Diabetes
Interventions: Upper endoscopy with small bowel biopsies and brushings., Blood draw, Stool sample; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Adult Spinal Deformity
Interventions: Routinely performed surgical correction of spinal deformity; Procedure
Lead sponsor: AO Foundation, AO Spine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: San Francisco, California • Louisville, Kentucky • Baltimore, Maryland + 5 more

Search by objective public record fields.

Institutional Outcome Data From Per-oral Plication of the Esophagus

Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Suprachoroidal Administration in Subjects With Metastases to the Choroid

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Human Epilepsy Project 2: Resistant Focal Seizures Study

Evaluation of Handheld Colonoscopy Force Monitor by Expert Endoscopists in the Performance of Colonoscopy

Study to Evaluate Recovery From Postoperative Pain After Sleep Apnea Surgery

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

In Vivo Assessment of Glutamine Utilization by Bone Marrow Plasma Cells

Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae

Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

MR-Guided Laser Ablation of Prostate Bed Recurrences

FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

Role of Intestinal Inflammation in the Pathogenesis of Type 1 Diabetes

Neurologic Complications in Spinal Deformity Surgery